B16 melanoma cell line (B16)

B16 melanoma is a syngeneic murine tumor cell line originally derived from a spontaneous melanoma in a C57BL/6 mouse in 1954 (Fidler, 1975). It serves as a foundational preclinical model in oncology and immunology for studying tumor progression, metastasis, and the efficacy of therapeutic interventions (Overwijk & Restifo, 2001). The line is characterized by its ability to produce melanin and its high transplantability in immunocompetent mice, making it ideal for evaluating immunotherapies such as checkpoint inhibitors and cancer vaccines (Teicher, 2001). Various sublines, most notably B16-F10, have been selected for specific properties like enhanced pulmonary metastatic potential (Fidler, 1973). While B16 cells are indispensable for drug discovery and mechanistic studies, they represent a complex biological system rather than a single molecular target (Khanna & Hunter, 2005). Researchers utilize this model to assess how drugs affect tumor volume and survival rates in a controlled laboratory environment.

Other names

B16 melanomaB16-F10B16-F1B16-F0B16-BL6Murine melanoma cell line

As a cell line model rather than a single molecular target, drugs interact with B16 cells through various mechanisms including direct cytotoxicity (DNA alkylation or microtubule inhibition), induction of apoptosis, or by modulating the immune microenvironment to facilitate T-cell mediated lysis of the cells (Overwijk & Restifo, 2001).